AZN

Astrazeneca Plc

Stocks

5 Best Dividend Stocks to Buy Now

by

There’s no better time than now to invest in dividend stocks.

And some of the best dividend stocks that beat the S&P 500’s average yield of 2.00% can be found in the healthcare sector.

Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a total of $220 billion in dividend cuts between the second and fourth quarters of 2020.

Since then, dividend payments jumped 26% to $471.7 billion.

And dividends paid to investors are expected to pay out $1.39 trillion by the end of the year.

We only have to look at one sector to find the best combination of yields and strong balance sheets.

Read more...

Technology

The Smart Way to Buy AAPL and MSFT… and Protect All Your Profits

by

As upbeat as the vaccine headlines have been recently, the virus and uncertainty over stimulus could send markets lower.

So, the smart move is to add to our positions in some of the year’s top tech performers (or any stock) with these two pro-level moves to “lock in” gains no matter what happens….

Read more...

Trading Strategies

How to Trade Pfizer Stock for a 290% Profit in a Month

by

Pfizer's recent news that their COVID-19 vaccine is 90% effective sent the market (and Pfizer's stock) soaring.

And while those who had already invested in the stock have made a nice return, Tom's going to show you the quick and easy way to almost quadruple your money on it…

Read more...

Stocks

The Best COVID-19 Stock to Buy Has Nothing to Do with Vaccines

by

Coronavirus vaccine stocks have been at the top of everyone's mind in 2020.

But the best COVID-19 stock is not a vaccine stock.

There are plenty of biotech stocks out there that could be vaccine candidates.

Of course, there's a rush on those as the White House seeks to accelerate COVID-19 vaccine production.

Read more...

dow jones

Dow Jones Now Up as White House Denies Any Threat to China-U.S. Trade Deal

by

The Dow Jones now is up on a positive report over the status of trade between the United States and China.

Last night, White House trade adviser Peter Navarro said that the deal between the world's two largest economies was over.

Navarro backtracked after other White House officials contradicted his earlier claims.

But that's not all carrying the Dow today.

Let's get into the report...

dow jones

Dow Jones Now Struggling Against a Bad Report from the IMF

by

The Dow Jones now faces resistance after the International Monetary Fund (IMF) reported banks across the world would struggle to be profitable due to COVID-19.

Markets are digesting the latest round of earnings reports.

China party leaders kick off the annual National People's Congress.

Let's talk about everything moving the Dow today...

Technology

Microsoft's "Right-Hand Man" Could Double Your Money Before the Economy Recovers

by

"We're living in a time of rapid change," is a phrase I hear often in the media these days. I think that's a big understatement.

The coronavirus pandemic has transformed the world and the markets in a little over a month.

Nevertheless, it's tough to imagine anything that would change my strong conviction on Microsoft.

I've made no secret of the fact that I believe "Mr. Softy" is one of the best plays in a $160 billion cloud computing sector that's grown stronger by the day since 2.5 billion people went under lockdown.

It's not hard to understand the catalyst for that: Governments, institutions, and individuals have little choice but to work and transact business remotely where- and whenever possible. That includes Microsoft itself, by the way.

Cloud computing and storage is absolutely critical for that effort.

So, my Microsoft recommendation stands, of course, but today, I want to look at another long-term buy.

This firm is closely allied with Microsoft – like my dad used to say, "People judge you by the company you keep."

The company I'm about to name is actually integral to Microsoft's own success, so much so that its earnings could double in the next three years… Full Story

The company I'm about to name is actually integral to Microsoft's own success, so much so that its earnings could double in the next three years... Full Story

Technology

The Answer to Big Pharma's Biggest Problem Could Double Your Money in Just Three Years

by

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.

With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.

It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.

And it's been doubling its earnings, on average, every 18 months...

Dow Jones

Dow Jones Industrial Average Falls 50 Points Ahead of Federal Reserve Rate Decision

by

The Dow Jones Industrial Average fell over 50 points in premarket trading as investors awaited news from today's Federal Reserve meeting on interest rates.

Markets largely ignored this morning's announcement that Americans seeking unemployment benefits came in at 214,000, a figure that was in-line with economists' expectations.

The Dow Jones surged more than 445 points yesterday after the Democrats secured the House of Representatives during the Midterm elections.